Payment overview · 2025
General Payments
$2,765.00
114 reported records · 25 companies
Healthcare provider profile · identity verified
Azeneth Hernandez
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · HOUSTON, TX · NPI 1376242578
Verified facts
What the public records show
CMS Open Payments records show Azeneth Hernandez received $2,765.00 in general payments during 2025 across 114 reported records.
Stryker Corporation accounted for 17.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 47 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Stryker Corporation | Unresolved — no canonical attribution shown | $495.28 | 17.9% | 29 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $416.80 | 15.1% | 19 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $304.64 | 11.0% | 5 | 2025 |
| CARDIVA MEDICAL, INC. | Unresolved — no canonical attribution shown | $175.69 | 6.3% | 9 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $172.65 | 6.2% | 4 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $169.91 | 6.2% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $155.65 | 5.6% | 4 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $107.57 | 3.9% | 4 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $94.42 | 3.4% | 4 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$84.29 | 3.0% | 4 | 2025 |
| Octapharma USA, Inc. | Unresolved — no canonical attribution shown | $71.71 | 2.6% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $71.03 | 2.6% | 4 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $58.25 | 2.1% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $57.74 | 2.1% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $52.46 | 1.9% | 3 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $51.25 | 1.9% | 2 | 2025 |
| ARGON MEDICAL DEVICES, INC. | Unresolved — no canonical attribution shown | $44.13 | 1.6% | 4 | 2025 |
| Imperative Care, Inc | Unresolved — no canonical attribution shown | $35.64 | 1.3% | 1 | 2025 |
| Teleflex LLC | Unresolved — no canonical attribution shown | $32.08 | 1.2% | 2 | 2025 |
| TriSalus Life Sciences, Inc. | Unresolved — no canonical attribution shown | $25.81 | 0.9% | 1 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $24.74 | 0.9% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $21.14 | 0.8% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.09 | 0.7% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.02 | 0.6% | 1 | 2025 |
| Inari Medical, Inc. | Unresolved — no canonical attribution shown | $5.01 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,765.00 | 114 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $182.78 | 4 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $172.65 | 4 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $172.65 | 4 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Inari Medical, Inc., Stryker Corporation | $165.85 | 12 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Inari Medical, Inc., Stryker Corporation | $165.85 | 12 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $164.01 | 2 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER Normalized: flowtriever |
Device | Stryker Corporation | $146.78 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $136.90 | 3 | 2025 |
Source payment records
|
|||||
| PASCAL Normalized: pascal |
Device | Edwards Lifesciences Corporation | $134.85 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $112.92 | 2 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $107.57 | 4 | 2025 |
Source payment records
|
|||||
| CLOTTRIEVER BOLD CATHETER Normalized: clottriever bold catheter |
Device | Stryker Corporation | $106.17 | 8 | 2025 |
Source payment records
|
|||||
| CARDIVA VASCADE 6/7F VCS Normalized: cardiva vascade 6 7f vcs |
Device | CARDIVA MEDICAL, INC. | $106.12 | 5 | 2025 |
Source payment records
|
|||||
| General - Vascular Intervention Normalized: general vascular intervention |
Device | Boston Scientific Corporation | $77.93 | 4 | 2025 |
Source payment records
|
|||||
| FIBRYGA Normalized: fibryga |
Biological | Octapharma USA, Inc. | $71.71 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $71.03 | 4 | 2025 |
Source payment records
|
|||||
| ARTIX MT Normalized: artix mt |
Device | Stryker Corporation | $70.90 | 4 | 2025 |
Source payment records
|
|||||
| CARDIVA VASCADE MVP XL VVCS 10-12F Normalized: cardiva vascade mvp xl vvcs 10 12f |
Device | CARDIVA MEDICAL, INC. | $66.29 | 3 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $58.25 | 3 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $57.74 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $52.46 | 3 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $51.25 | 2 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $51.25 | 2 | 2025 |
Source payment records
|
|||||
| COREVALVE EVOLUT R Normalized: corevalve evolut r |
Device | Medtronic, Inc. | $48.42 | 2 | 2025 |
Source payment records
|
|||||
| CLOT MANAGEMENT Normalized: clot management |
Device | ARGON MEDICAL DEVICES, INC. | $44.13 | 4 | 2025 |
Source payment records
|
|||||
| ROTAPRO Normalized: rotapro |
Device | Boston Scientific Corporation | $39.76 | 2 | 2025 |
Source payment records
|
|||||
| ELUVIA Normalized: eluvia |
Device | Boston Scientific Corporation | $35.87 | 2 | 2025 |
Source payment records
|
|||||
| PRODIGY CATHETER Normalized: prodigy catheter |
Device | Imperative Care, Inc | $35.64 | 1 | 2025 |
Source payment records
|
|||||
| EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Normalized: edwards sapien 3 transcatheter heart valve thv |
Device | Edwards Lifesciences Corporation | $35.06 | 1 | 2025 |
Source payment records
|
|||||
| EkoSonic Normalized: ekosonic |
Device | Boston Scientific Corporation | $29.12 | 1 | 2025 |
Source payment records
|
|||||
| General - Therapies Normalized: general therapies |
Device | Boston Scientific Corporation | $27.28 | 3 | 2025 |
Source payment records
|
|||||
| TRINAV INFUSION SYSTEM Normalized: trinav infusion system |
Device | TriSalus Life Sciences, Inc. | $25.81 | 1 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $24.74 | 1 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $21.14 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $20.09 | 1 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $19.38 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $18.75 | 1 | 2025 |
Source payment records
|
|||||
| RESONATE EL ICD VR Normalized: resonate el icd vr |
Device | Boston Scientific Corporation | $18.47 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $17.02 | 1 | 2025 |
Source payment records
|
|||||
| TURNPIKE Normalized: turnpike |
Device | Teleflex LLC | $16.51 | 1 | 2025 |
Source payment records
|
|||||
| LINQ II Normalized: linq ii |
Device | Medtronic, Inc. | $16.49 | 1 | 2025 |
Source payment records
|
|||||
| GUIDELINER Normalized: guideliner |
Device | Teleflex LLC | $15.57 | 1 | 2025 |
Source payment records
|
|||||
| General - Balloon Catheters Normalized: general balloon catheters |
Device | Boston Scientific Corporation | $14.54 | 1 | 2025 |
Source payment records
|
|||||
| VENACORE THROMBECTOMY CATHETER Normalized: venacore thrombectomy catheter |
Device | Stryker Corporation | $10.59 | 1 | 2025 |
Source payment records
|
|||||
| OptiCross 6 Normalized: opticross 6 |
Device | Boston Scientific Corporation | $5.59 | 2 | 2025 |
Source payment records
|
|||||
| AVVIGO Guidance System Normalized: avvigo guidance system |
Device | Boston Scientific Corporation | $4.23 | 1 | 2025 |
Source payment records
|
|||||
| CARDIVA VASCADE MVP VVCS 6-12F Normalized: cardiva vascade mvp vvcs 6 12f |
Device | CARDIVA MEDICAL, INC. | $3.28 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Metoprolol Succinate | Metoprolol Succinate | 24 | 14 |
| Atorvastatin Calcium | Atorvastatin Calcium | 22 | 14 |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 13 | suppressed |
| Lisinopril | Lisinopril | 12 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 12 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,765.00 · 114 records | Stryker Corporation | ARTIX MT, AVVIGO Guidance System, CAMZYOS, CARDIVA VASCADE 6/7F VCS, CARDIVA VASCADE MVP VVCS 6-12F, CARDIVA VASCADE MVP XL VVCS 10-12F, CLOT MANAGEMENT, CLOTTRIEVER BOLD CATHETER, COREVALVE EVOLUT R, CT THROMBECTOMY SYSTEM KIT, EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV), ELUVIA, EkoSonic, FIBRYGA, FLOWTRIEVER, FLOWTRIEVER CATHETER, S, FUROSCIX, Flexitouch Plus, GUIDELINER, General - Balloon Catheters, General - Therapies, General - Vascular Intervention, JARDIANCE, Kerendia, LEQVIO, LINQ II, LifeVest, Nimbl, OPSUMIT, OptiCross 6, Ozempic, PASCAL, PRODIGY CATHETER, REPATHA, RESONATE EL ICD VR, ROTAPRO, Rybelsus, SYMPLICITY G3, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, TRINAV INFUSION SYSTEM, TURNPIKE, UPTRAVI, VENACORE THROMBECTOMY CATHETER, VERQUVO, WAINUA, WATCHMAN Access System, Wegovy | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error